P2RY12 and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss: For studies that assessed the P2Y12 inhibitor in the prevention of new-onset MHA after transcatheter ASDC, the mean age of the patients was 37.7 years, and one trial [13] also enrolled pediatric patients aged from 4 to 79 years.